Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024)
Mimedx's (MDXG) quarterly Cash from Discontinued Operations came in at $1000.0 in Q4 2024, down 99.9% year-over-year from $987000.0 in Q1 2024, and up 200.0% quarter-over-quarter from -$1000.0 in Q3 2024.
Powered by 
Analysis
Mimedx (MDXG) Cash from Discontinued Operations (2023 - 2024) Analysis & Trends
Mimedx has disclosed Cash from Discontinued Operations across 2 years of filings, most recently posting $1000.0 for Q4 2024.
- In Q4 2024, Cash from Discontinued Operations fell 99.9% year-over-year to $1000.0; the TTM figure through Sep 2025 stood at $1000.0 (down 98.21% YoY), while the FY2024 annual figure was -$930000.0, up 88.61% from the prior year.
- Cash from Discontinued Operations came in at $1000.0 for Q4 2024 at Mimedx, up from -$1000.0 in the prior quarter.
- In the past five years, Cash from Discontinued Operations ranged from a high of $987000.0 in Q4 2023 to a low of -$4.6 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.74 Bn | 175.14 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 127.56 Bn | 122.34 Bn | 1.96 Bn | - |
| 3 | Medtronic | 116.90 Bn | 108.08 Bn | 6.34 Bn | - |
| 4 | Stryker | 103.85 Bn | 100.37 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.70 Bn | 63.16 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 49.88 Bn | 45.63 Bn | 1.35 Bn | - |
| 7 | Alcon | 33.04 Bn | 31.59 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn | - |
| 9 | Steris | 20.65 Bn | 20.17 Bn | 684.20 Mn | - |
| 10 | Mimedx | 670.99 Mn | 535.15 Mn | 44.38 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -123,000.00 |
| Mar 31, 2024 | -807,000.00 |
| Dec 31, 2023 | 987,000.00 |
| Sep 30, 2023 | -309,000.00 |
| Jun 30, 2023 | -4.19 Mn |
| Mar 31, 2023 | -4.65 Mn |